Financial Data and Key Metrics Changes - The company ended the quarter with $509 million in cash [67] - Cash burn for Q1 2025 was approximately $118 million, excluding partnership inflows and non-cash effects [68] - The company expects a cash runway extending into mid-2027 based on current operational adjustments and partnerships [69][70] Business Line Data and Key Metrics Changes - The company is focusing on five clinical and preclinical programs with a higher probability of success, particularly in oncology and rare diseases [12][13] - The pipeline reflects a strategic application of Recursion OS and AI, emphasizing differentiated medicines [12][13] - The company has deprioritized three programs: NF2, CCM, and C. Diff, while placing LSD1 on strategic pause [13][22][27] Market Data and Key Metrics Changes - The company has generated over $450 million from partnerships, including four collaborations with Sanofi [7][70] - The partnership with Roche has led to significant advancements in disease context-specific maps, enhancing discovery speed [63] Company Strategy and Development Direction - The company aims to build a learning system that improves drug discovery and development through its Recursion operating system [2][4] - There is a commitment to disciplined capital allocation and prioritizing programs that meet high standards of differentiation [30][65] - The focus is on leveraging AI throughout the drug development process to enhance efficiency and effectiveness [76] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenging macroeconomic environment and emphasizes the need for disciplined decision-making [6] - The company is optimistic about the potential for significant milestones from existing partnerships and internal programs [75][76] Other Important Information - The company plans to make all clinical data publicly available in peer-reviewed journals following appropriate review [28] - The integration of Recursion and Exensia has strengthened the company's capabilities and pipeline [4][6] Q&A Session Summary Question: What burn rate do you anticipate exiting 2025 or entering 2026 with? - The company has not provided specific guidance but targets a budget of $450 million or less for the year, aiming to extend the runway without impacting execution [78][79] Question: When can we see an option on a molecule candidate from one of your partnerships? - The company has already optioned four programs with Sanofi and is optimistic about future options and potential later-stage transitions into partners' pipelines [82] Question: What new levers in the OS are being used to accelerate partnership programs to commercialization? - The company is enhancing its understanding of biology and patient populations through multimodal data, improving chemistry and design processes, and modeling drug-like properties earlier in development [83]

Core Insights - Recursion reported business updates and financial results for Q1 2025, emphasizing its commitment to advancing medicines in high unmet need areas through a streamlined portfolio strategy [1][3][5] Business Highlights - The company is focusing on high-potential programs to accelerate treatments, leveraging its integrated Recursion OS platform [3][5] - Recursion has deprioritized three clinical programs and one preclinical program after a strategic review, aiming to concentrate resources on programs with the strongest scientific rationale [5][9] - The pipeline includes several candidates in various stages, with REC-4881 showing promising preliminary data in familial adenomatous polyposis [6][8] Financial Results - Total revenue for Q1 2025 was $15 million, a slight increase from $14 million in Q1 2024, primarily due to collaboration agreements [16] - Research and development expenses rose to $130 million in Q1 2025 from $68 million in Q1 2024, driven by agreements with Tempus and the business combination with Exscientia [16] - The net loss for Q1 2025 was $203 million, compared to a net loss of $91.4 million in Q1 2024 [21] Cash Position - As of March 31, 2025, cash and cash equivalents were $509 million, down from $603 million at the end of 2024 [16][24] - The company expects a cash burn of up to $450 million for 2025, with a projected cash runway extending into mid-2027 [21][12] Partnerships and Collaborations - Recursion achieved a milestone in its collaboration with Sanofi, generating $7 million, with potential for over $300 million in additional milestone payments [9] - The partnership with Roche and Genentech continues to yield novel biological insights, with significant data generated from over one trillion iPSC-derived cells [10] Pipeline Updates - The company is advancing a focused set of clinical and preclinical programs in oncology and rare diseases, with several candidates expected to progress through various phases in the coming years [5][8][14] - REC-7735 is targeting PI3Kα H1047R mutant breast cancer, with candidate profiling ongoing and a development candidate expected in 2H25 [8][14]

Investment Rating - The report indicates a positive investment outlook for the techbio sector, highlighting its transformation into a major global asset class with significant growth potential driven by emerging VC managers [3][4]. Core Insights - The techbio sector has evolved from a niche segment to a major global asset class over the past two decades, with emerging VC managers playing a crucial role in this growth despite broader market challenges [3][4]. - A platform-first investment philosophy is prevalent, focusing on technologies applicable across multiple biological domains, which enhances risk distribution and portfolio diversification [3][6]. - High-growth investment frontiers are emerging, particularly in AI-powered drug discovery, synthetic and computational biology, and lab automation technologies, presenting substantial investment opportunities [3][8][9][10]. - The investor landscape is diversifying, with traditional tech VCs entering the biology space, specialist techbio investors gaining prominence, and corporate venture arms making strategic investments [3][11]. - Future trends suggest consolidation and validation, with specialized megafunds focusing on computational biology as AI-discovered therapeutics advance [3][4]. Summary by Sections Key Takeaways - The techbio sector has transformed significantly, with emerging VC managers driving growth [3]. - A platform-first investment philosophy is dominating the space, providing economic advantages [3][6]. - High-growth investment frontiers include AI-powered drug discovery and lab automation technologies [3][8][9][10]. - The investor landscape is diversifying with traditional and specialist investors [3][11]. - Future trends indicate consolidation and a focus on computational biology [3][4]. Techbio Investor Highlights - The techbio sector has grown into a major global asset class, with emerging VC managers playing a pivotal role [4]. - Techbio fund formation has shown resilience despite market challenges, with notable funds closing successfully [5]. - A platform-first approach is reshaping investment strategies, emphasizing foundational technologies [6][7]. High-Growth Investment Frontiers - AI-powered drug discovery platforms are leveraging machine learning for accelerated development [8]. - Investments in synthetic and computational biology are enabling precision biology innovations [9]. - Automation and bioinfrastructure investments are enhancing laboratory capabilities [10]. The Money Movers - Traditional tech VCs are increasingly investing in techbio, often launching dedicated funds [11][12]. - Notable investors like Andreessen Horowitz and Pear VC are actively participating in the techbio space [12][16]. The Specialists - Dedicated life sciences venture firms are emerging, focusing on techbio investments [19]. - Firms like Civilization Ventures and Foresite Capital are leading in specialized investments [20][23]. The Corporate Kingmakers - Corporate venture arms like Google Ventures and NVentures are driving innovation in techbio [30][35]. - These firms leverage their corporate ecosystems to identify high-potential investments [30]. The Emerging Managers - New entrants like Atria Ventures are reshaping the techbio investment landscape [39]. - These firms focus on early-stage opportunities at the intersection of AI and biology [39][40]. The Next Wave of Techbio Investment - Specialization and capital concentration are expected to accelerate in the coming years [45]. - Clinical validation of AI-discovered therapeutics will influence future funding allocations [49]. - Investments in precision medicine and pharma automation technologies are projected to surge [50][51].